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AKTIVITI ANTIHIPERTENSIF 
ANALOG-ANALOG KLONIDIN PENUKARGANTIAN 
PARA DAN TERBITAN-TERBITAN ASILNYA. 
Kegunaan klonidin sebagai ubat dalam regimen-regimen 
antihipertensif adalah terhad disebabkan keujudannya 
hipertensi pantulan semasa pemberian ubat dihe~tikan 
secara mengej ut. Adalah tidak diketahui kemu~gkinan 
pengasingan efek hipertensi pantulan daripada a~tiviti 
hipotensif dapat dilakukan melalui perubahah dalam 
struktur induk. Kajian ini telah menumpu pernatian 
kepada efek penukargantian para dan pengasila~-N ke 
atas potensi hipotensif, hipertensi pantulan dan 
selektivit~ un:uk adrenoseptor-a. Ak:iviti 
antihipertensif dan kemungkina~nya kejadian hipertensi 
pantulan sebelas analog-analog dibandingkan dengan 
l<.lo~idin dalam haiwan-haiwan SHR. Pember ian 
56 nmol./kg secara intraperitoneal selama 2S hari 
kepada SHR yang diikuti dengan pemberhentian mengejut 
tidak menunjukkan aktiviti hipertensif yang berkesan 
diantara analog-analog kecuali sebatian AL-1.2. 
Semasa fasa pemberhentian tekanan darah sistolik cikus-
tikus yang dirawati dengan AL-1.2 tidak menunjukkan 
kesan peningkatan pant ulan a tau 11 overshoot 11 • 
Ketiadaan hipertensi pantulan dipercayai disebabkan 
oleh penukargantian para kumpulan isobutiril. ?eranan 
XVII 
pengasilan-N tidak oegitu jelas. ?emberian intravena 
dalam tikus normote~sif terbius dengan pentobarbiton 
menunJukkan kekurangan dalam efikasi hipotensi analog-
analog berbanding dengan klonidin. Penukargantian para 
dengan kumpulan nitril hampir sama sek·ali menghilangkan 
aktiviti hipotensif tetapi gantian dengan kumpulan 
hidroksilmetil dan karboetoksil membenarkan 
pembendungan sedikit aktiviti hipotensif. Dalam 
eksperimen yang sarr.a di mana denyutan jan tung diuj i, 
pengasilan-N kelihatan hampir sama-sekali menghilangkan 
kesan bradikardia jika dibandingkan dengan 
penukargantian para yang kurang berkesan. Dalam 
persediaan anococcygeus yang telah digunakan untuk 
meni lai akt i viti ra:-:gsangan adrenoseptor- a 1 , adalah 
dikelihatan bar.::t'lla .sebat=.an-sebatian CL-1.1, CL-1.2, 
AL-1.0, AL-1.1 dan AL-1.2 mempamerkan perangsangan 
adrenoseptor-a 1 yang lemah. AL-1.2 telah menunjukkan 
afiniti untuk adrenoseptor-a 1 yang terendah dan 
autoinhibisi pada dos-dos yang lebih tinggi. Dalam 
persediaan vas deferens tikus terasingan yang telah 
digunakan untuk menilai aktiviti adrenoseptor-a 2 
presinaptik, adalah diperhatikan bahawa untuk aktiviti 
agonisme ~drenoseptor-a 2 yang tinggi, tapak para perlu 
dikosongkan. Tambahan pula, untuk afiniti-a 2 yang 
tinggi sekurang-kurangnya satu nitrogen imidazolin 
diperlukan bebas. 
XVII:: 
ABSTRACT 
The use of clonidine in antihypertensive drug regimens 
has been severely limited by tr.e appearance of 
withdrawal hypertension upon, abrupt discontinuation of 
treatment. It is not known if a separation of rebound 
hypertension from hypotensive activity is possible 
through structural alteration. The present 
investigation involved a study of the effects of 
p-substitution and N-acylation of clonidine on the 
hypotensive potency, rebound hypertension and 
a-adrenocepcor selectivity. The antihypertensive 
activity and potential for exhibiting withdrawal 
hypertension of eleven analogues were compared to 
cronidine in Spontaneously Hypertensive Rats(SHRs). 
Intraperitoneal ad~inistration at 56 nmol./kg over a 
period of 20 days in the SHRs followed by abrupt 
withdrawal did not re'Jeal significant antihypertensive 
activity in any of the analogues except for AL-1.2. 
During the withdrawal phase, the systolic blood 
pressure of AL-1.2-treated rats did not show a rebound 
increase or overshoot. The absence of rebound 
hypertension was believed to be due to the isobutyryl 
functional group in the para position. The role of 
N-acylation was unclear. The intravenous 
administration in pentobarbitone-anesthetized 
XIX 
nc:::-:-.0tens i ve rats revealed a lower hypotensive efficacy 
in =omparison to clonidine. p-Substitution with 
ni:~ile functional groups resulted in compounds with 
al~:st no hypotensive activity while an appreciable 
amc~nt of activity was retained in compounds with 
p-s~bstitutions involving the hydroxylmethyl and 
car~oethoxyl functional groups. In the same 
ex~~riments in which heart rate was monitored, 
N-a=ylation was more effective in reducing bradycardia 
whe~ compared to p-substitution. In the rat 
anc=0ccygeus preparation, it was observed that the 
corr.;:>unds CL-1.1, CL-1.2, AL-1.0, AL-1.1 and AL-1.2 
dis;~ayed weak a 1 -adrenoceptor stimulatory activity. 
AL-~.2 had the lowest affinity for a 1 -adrenoceptors and 
dis;:ayed auto1ntibition at highe:: doses. In the 
isc:~:ed rat vas deferens which was used to assess 
pres~·:-1aptic a 2 -adrenoceptor activity, it was obs_erved 
tha~ for high a 2 -adrenoceptor agonist activity, the 
para Dosition should be left unsubstituted. Further, 
for ~~gh a 2 -affinity at least one i~idazolidine nitro-
gen should be left unsubstituted. 
XX 
INTRODUCTION 
/ 
1.0. Introduction 
Hypertension may be defined as a condition of raised 
blood pressure whi~h is persistently elevated beyond 
nor~al limits. If the cause cannot be clearly 
defined, ic is termed as primary or essential 
hypertension. Secondary hypertension is the condition 
where the cause is known and this may be in the form of 
an imbalance in endocrine function, kidney disease, 
hypertension in pregnancy and that resulting from the 
use of contraceptive pills. 
Alt~cugh it is impossible to clearly define normal or 
abn~~~a~ blocd pressure, the World Health Organisation 
has 9rovided :he following guideline for consideration 
in :.::.e diagnosis of the disease (WHO, 1978). Blood 
pressure can be considered normal for an adult with a 
sys:c~ic pressure equal to or below 140 mmHg and a 
dias:cli= pressure equal to or below 90 mmHg. An 
in d i vi d 1..:. a 1 i s cons ide red hyper tens i v e i f s y s to l i c 
pressure equals to or exceeds 160 mmHg and the 
diastolic,pressure is equal to or greater than 95 mmHg. 
Whatever the difficulties there may be in identifying 
hypertensive individuals, hypertension if left 
untreated will increase the risks of ~evelopment and 
1 
dea:h from cardiovascular disease. Persistently 
el~va:ed blood pressure will lead to irreversible 
cha~ges in the walls of blood vessels. There is an 
increase in peripheral resistance and the left 
ve~cricle of the heart gradually becomes 
hypertrophied. The blood vessels of the heart undergo 
adap:ive changes with the lumen becoming progressively 
sma~~~r. Eventually lesions develop in the heart due 
to ischaemia and the result is heart failure. Cerebral 
strc~e and damage to blood vessels in the kidney are 
oth~r complications of raised arterial 
pressure (Sleight, 1977) Reducing elevated blood 
pressure is thus the primary objective of 
anti~ypertensive therapy and will drastically reduce 
the risks of many cardiovascular complications and 
reverse the structural changes seen in the vasculature. 
Hyper:ension may be treated in part by a modification 
in ~ifestyle such as the avoidance of stress, a low 
sal: diet, maintenance of normal bodyweight, regular 
exercise and immediate cessation of smoking. Drug 
therapy remains the main approach in relieving 
hypertens~on and a large number of drugs(Van Zwieten 
1984) are presently available for this purpose. They 
are classified in table 1 shown below. 
2 
Table 1. 
Classification of antihypertensive drugs 
Class 
1. Beta-adrenoceptor 
blocking agents 
2. Alpha-adrenoceptor blocking 
agents 
3. Adrenergic and Beta 
adrenoceptor blocking drugs 
4. Angiotensin-converting enzyme 
inhibitors 
5. Calcium-chancel backing 
agents 
6. Ci~ec~-acti.~g vasodilators 
7. Cent~ally ac:ing agents 
9. Ganglion-blocking agents 
10. Adrenergic neurone blocking 
agents 
11. Angiotensin-IT receptor 
blocking agents 
12. Inhibitors of renin 
13. Serotonin blocking agent 
3 
Drugs 
Atenolol 
Metoprolol 
Propranolol 
Prazosin 
Phentolamine 
Phenoxybenzamine 
Labetolol 
Captopril 
Enalapril 
Nifedipine 
Diazoxide 
Hydralazine 
Clonidine 
Guanabenz 
Guanfacine 
Methyldopa 
Hydrochlorothiazide 
Trimetaphan 
~eserpine 
.3ethanidine 
Guanethidine 
Saralasin 
pepstatin 
Ketanserin 
While ~he primary pharmacological action of many of 
these agents are known, the exact mechariisms by which 
they ace to reducing blood pressure in the long term 
' 
are ~~~ clearly understood. Since antihypertensive 
thera~y involves prolonged administration of one or 
more :f these drugs .in combination, there is the 
possic~lity that many of the patients will experience 
side-e:fects. Patients unable to tolerate che side-
effec=s may require a change in the drug or treatment 
combi~ation used and this would be facilitated by 
havins a broad range to choose from. It is worthwhile 
there:~re, to experiment with new compounds with a 
clear:..;· understood mode of action which could provide 
good ::ntrol of blood pressure and be relatively free 
or ha~e a reduced number of side-effects They may 
not ~e:essarily be more active compounds. 
1.1. The regulation of blood pressure 
A nu~ter of mechanisms involved in the control of blood 
pressc:.::.·e have been identified ( Struyker Boudier, 1984) . 
Among :hem are neural, endocrine, renal and vascular 
mecha~~sms. 
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1.1.1. Neural mechanisms 
Neural mechanisms are most important for the rapid 
stabilisation of blood pressure. They are further 
subdivided into the sinoaortic baroreceptor, the 
cardiopulmonary baroreceptor, the chemoreceptor, the 
central nervous system ischaemic, somatic afferent and 
the renal afferent reflexes. 
l.l.l(a). The sinoaortic baroreceptor reflex 
The s~~oaortic baroreceptor reflex acts by detecting 
changes in arterial press~re through its stretch 
sensic~ve receptors located in the aortic arch and the 
carc~~j bifurcation. Informacion is then transmitted 
along afferent nerves to the central nervous system. 
The response that ·follows invo~ves both the sympathetic 
and ~arasympathetic nervous system and has direct 
conseq~ences on the heart and vasculature. It is the 
most ~mportant of the neural control mechanisms. 
Baroreceptors function with~n a certain minimum or 
maximum pressure limit. They are activated above a 
certai~ minimum level and t~eir activity does not 
increase above a certain maxi~~m pressure level. They 
also show reflex adaptation in that they may reset to 
5 
higher pressGre thresholds at which they are activated, 
for instance in hypertensive individuals. 
l.l.l(b). The cardiopulmonary baroreceptor reflex 
This reflex detects changes in blood volume of the 
circulation chrough stretch-sensitive receptors located 
in the atrium and pulmonary arteries. Renal function 
is influenced by the activity of these reflexes and it 
has been shown that increased receptor activity may 
cause inhibition of renin release and also affect the 
water balance of the body. 
l.l.l(c). Other reflexes 
The chemoreceptor, central nervous system ischemic, 
somacic afferent and renal afferent reflexes are less 
important in ~he acute control of blood pressure. The 
central nervous system ischaemic reflex only functions 
when there is a drastic drop in mean arterial pressure 
/ 
below 40-50 mmHg. The result is a very large increase 
in sympathetic nervous activity aimed at restoring 
normal blood pressure. 
6 
1.1. 2. Hormonal mechanisms 
The·/ are divided into those involving the 
catr.:::colamines, renin-angiotensin system, aldosterone, 
an t :_ :i i u r e t i c h o r m one , p r o s t a g l and i n s , ''a s o a c t i v e 
pri~ciples and natriuretic hormone. The role of 
hcrm~~al mechanisms in the long term control of blood 
press~re are relatively minor. 
1.1.2(a). The cathecolamines 
The =~thecolamines like adrenaline and noradrenaline 
are ~~rcially responsible for the maintenance of 
vasc __ 3.r 
rece:::::J~ 
role 
cone by their action on a 1 and a 2 -adrenergic 
subtypes present in the blood vessels. Their 
che pathogenesis of hypertension remains 
cont r:·.rers ial. Plasma noradrenaline has been found to 
be e:evated in only some studies of patients 
esse~:ial hypertension(Goldstein, 1981) 
1.1.2 (b) The renin-angiotensin system 
with 
Renin, secreted by the juxtaglomerular apparatus of the 
kidney is an inactive molecule. In the plasma, renin 
acts on an angiotensinogen co form angiotensin-I. 
7 
Angic::ensin converting enzyme facilitates the conversion 
of A~~iocensin-I into angiotensin-!! which is the 
phar~~~ologically active molecule. Angiotensin-II has 
direc:: vascular effects and causes constriction of 
veins ~nd arteries. Vascular permeability is increased. 
Renal sodium and water excretion is altered. The 
synthesis and release of aldosterone is stimulated by 
angic::ensin-II and by increases in sympathetic nerve 
activ~~y via both a central nervous system mechanism 
and a peripheral presynaptic effect. The role of 
aldos::erone in the regulation of blood pressure is 
brief:~ described below. 
l.l.2(c). Aldosterone 
Aldos::~~one is a mineralocorticoid hormone secreted by 
the zc~~ glomerulosa cells of the adrenal cortex. The 
hormo~s has its primary role in enhancing the renal 
tubul~~ reabsorption of sodium in exchange for 
potass~um and hydrogen ions. This results in an 
expansion of blood volume. A:terations in the renin-
angiocens~n system regulates the the secretion of 
aldoste:cone. Angiotensisn-II is the main stimulus for 
the re:ease of aldosterone as described previously. 
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1.1.2(d). Antidiuretic hormone 
The antidiuretic hormone(ADH) or vasopressin is 
secr~ted by the neurohypophysis. Secretion of this 
' hormone is promoted by a fall in plasma volume as well 
as a~ increase in plasma osmotic pressure. This causes 
an i~2rease in the reabsorption of water in the distal 
tubu:es and collecting ducts of the kidney. Other 
factsrs also modulate the release of this 
hormone(Bayliss, 1977). ADH has also been implicated 
as a contributory factor toward raised arterial 
press~re in hypertension because of its vasoconstrictor 
effec~s on vascular smooth muscle(Monos et al, 1978). 
1.1.2(e). Vasoactive substances 
These are composed of mainly the prostaglandins, the 
kalle~krin-kinin system, the antihypertensive principle 
of the renal medulla and the natriuretic hormone. The 
prostaglandins are thought to function as local tissue 
hormones adjusting the local blood flow to the changing 
metabolic /requirements of the tissue. The kalleikrin-
kinin system has components in the plasma, the exocrine 
glands and the kidney. Kinins are formed from plasma 
subscrates called kininogens by the action of 
kalleikrin. Kinins are potent vasodilat0rs and affect 
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sod~~~ and water reabsorption in the distal tubules. 
The a~:ihypertensive principle and che natriuretic 
hor~~~e have not yet been clearly identified. The:.::.: 
ro~e. much like the role of the prostaglandins ar.d 
kal~e:.krin-kinin have not been clearly established. 
1.1.3. Renal mechanisms 
Some cf the ~hanges in arterial pressure brought about 
by ~eural and endocrine mechanisms involve a~ 
altera::.cn in renal function. On its own, however, the 
kici~ef ~as a dominant function in the long-term 
mai~=e~ar.ce of arterial pressure(Borst & Borst-De Geus, 
This has been attributed to the intimate 
rela=~c~shio between renal perfusion pressure and renal 
cut~~= which under normal circumsta~ces are equal. 
Sli~~= increases in perfusion pressure cause a very 
:arse increase in glomerular filtration rate. After 
somec~me, extracellular volume and blood volume 
decrease and return to pre-existing levels. The 
impcrcant role of the kidney in long-term maintenance 
of :C:Cood' pressure does not presuppose that the 
causative factor of hypertension lies in this organ. 
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1.1.4. Vascular mechanisms 
Like ~2nal function, vascular mechanisms are controlled 
in pa~t by neural and endocrine mechanisms. A number 
of o~gans such as the brain, the kidneys and heart 
regula~e their own blood flow ln response to changing 
stimu:i such as stretch(pressure) and chemical factors 
such as oxygen and other blood-borne substances. In 
the long term control of blood pressure, changes may 
occu~ in the walls of these vessels. There may be an 
increase in vascularity or a thickening of the walls of 
blooci vessels as seen in hig:: blood pressure 
condi::..ons. 
1.2. The role of a-adrenoceptors in the regulation 
of blood pressure. 
1.2.1. Classification 
a-Ad~enoceptors that are located within the 
cardiovascular system play an important role in the 
/ 
regulacion of blood pressure in the body. They are 
also :~e targets for a wide range of therapeutically 
usefu~ antihypertensive drugs. a-Adrenoceptors belong 
to two subgroups namely a and B as proposed by 
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Ahlq-:...:.ist (1948). A further division was later proposed 
in which a-adrenoceptors were divided into ry~ and ry 2 
subt:r;)es and JS-adrencceptors into JS 1 and JS 2 
subcy:;::::s (Langer, 1974) The anatomical location of 
a 1 -adrenoc~ptors was pest-junctional and chat of 
a 2 -adrenoceptors, pre-junc~ional. Receptors cf the a 2 
subty~e were later shown to be present postjunctionally 
makl~; the anatomical c:assification of receptor 
subty:;:es by location inappropriate(Timmermans & Van 
Zwiec::::-., 1982). A pharmac~logical classification based 
on r:::::eptor demand ( Ruffol~ e t al, 19 91) is presently 
used i~ the classificatio~ of a-adrenoceptor subtypes. 
In t~i.s classification, an ry 1 -adrenoceptor responds 
toward stimulation by r.ethoxamine, cirazoline or 
phe:--.;·:..:::phrine and the r:::sponses are compe:::.itively 
anta~:::1ized by WB-41C::. or corynanthine. An 
a 2 -ad~enoceptor is stimula:ed by UK-14,301, B-HT 920 I 
8-HT ~33 or a-methylnore:;:inephrine and the responses 
bloc~ed competitively ~y low concentrations of 
yohi~~i.ne, rauwolscine or ~dazoxan. 
1.2.2. Distribution of a-adrenoceptors 
' 
participating in blood pressure regulation. 
The presence of a-adrenoceptors in various tissues to 
some extent explains the probable mechanisms by which 
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so~~ antihypertensive drugs act. In the peripheral 
circulation, both a 1 and a 2 receptor subtypes are 
present on the smooth muscle cell membranes of the 
arteries(Timmermans et al, 1990). Stimulation of a 1 
and a 2 -adrenoceptors evokes vasoconstriction. 
In the veins, boch receptor subtypes are present and 
are thought to be responsible for the maintenance of 
venous tone. Blockade of a 1 -adrenoceptors, for example 
with prazosin causes vasodilatation. 
a-Adrenoceptors are also present in the heart. They 
are mainly of the a 1 subtype(Timmermans et al, 1990) 
and ~ediate increases in heart rate and contractility. 
The presence of a 2 -adrenoceptors have not been 
demcnscrated. Clonidine depresses heart rate and it is 
believed :hat this effect is mediated by its action on 
It has already been mentioned previously thac renal 
function is of considerable importance to the long-term 
contrcl ~f blood pressure. It is richly innervated by 
noradrenergic neurones which extend to the afferent and 
efferent arterioles, the juxtaglomerular apparatus, the 
nephrons and the collecting ducts. Adrenergic 
receptors chat are present are mainly of the a 2 subtype 
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wit~ a 1 -adrenoceptors being less abundant. Renal 
exc~~cory functions are controlled by a-adrenoceptors. 
Stiffi~lation of a 1 -adrenoceptors is thought to promote 
the ~ubular reabsorption of sodium and water while 
sti~·..:lation of extrasyn~ptically located 
a 2 -adrenoceptors by catecholamines results in opposing 
ef:e~~s(Olson, 1976) 
The ~entral nervous system controls many important 
physiological functions. In particular, the 
poncc~edullary region contains the vital centres 
regu~ating respiratory, cardiac and vasomotor function 
whic~ are contained in the grey matter. Motor and 
sens~~y fibres that are present interconnect these 
cen~:~s with higher brain centres and with various 
recec~crs such as those involved in baroreceptor and 
care;: i ::i sinus occlusion ref lex (Chalmers, 19 75) . The 
prese~ce of a dense adrenergic innervation has made 
this ~egion a natural target for centrally acting 
hypc~ensive drugs which are thought to act by 
interacting with a-adrenoceptors. 
subtypes are present in the brain. Research so far has 
centred mainly on the interaction of hypotensive drugs 
I 
with a 2 -adrenoceptors. The role played by 
a 1 -adrenoceptors in mediating the response of blood 
pressure toward antihypertensive drugs remain unclear. 
The soinal cord has been shown to contain 
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a-adrenoceptors of the a 2 subtype(Kubo et al, 1987) 
th::;.c may play a role in the regulation of blood 
pressure. 
1.3. Interaction of antihypertensive drugs and blood 
pressure control mechanisms. 
The process by which an antihypertensive drug lowers 
bleed pressure is complex and depends on the 
pha~~acological action of the drug at the cellular 
level and responsiveness of other regulatory 
mec~::;.nisms. This interaction occurs at different levels 
and often more than one mechanis~ may be involved. 
Whe:-. hemodynamic parameters are altered, other 
mec~anisms are activated either through reflex 
pat::.· .. ays, for example, the baroreceptor reflex, which 
may ~n turn stimulate the release of ADH. Renal 
exc~e:ory function may be altered :o adapt to changes 
in t~ood pressure in order co maintain normal fluid 
bala~ce. As a result of this, there is a gradual shift 
in t:~od pressure from the previous level to a new set-
pou-:::. Prolonged therapy also allows the chronic 
effects of antihypertensive therapy to be known. The 
reversal of structural changes commonly seen in 
hyper~nsive disease(Struyker Boudier, 1984) may also 
be observed in the vasculature during this time. 
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1.4. a-Adrenergic agonists 
They may be divided into two major groups. These are 
the phenethylamines and the imidazoli(di)nes. The 
first group includes the compounds phenylephrine and 
methoxamine which are specific for a 1 -adrenergic 
receptors. In the second group are clonidine, 
naphazoline and xylometazoline. Clonidine is specific 
for ~ 2 -adrenoceptors with the latter two being 
relatively non-specific(Timmermans et al, 1990). 
Clonidine has a potent central hypotensive 
action(Constantine & McShane, 1968; Bolme & Fuxe, 
1971; . The structure and pharmacological actions of 
clonidine are discussed in more detail below. 
1.4.1. Clonidine 
Cloni.:ii.r-:e or 2- ( 2, 6 -dichlorophenyl imino) -2- imidazol idine 
was ~i.rst synthesized in 1962. The structure is 
depicted in figure 1 below. 
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1.4.1(a) Mechanism of action 
The centrally mediated hypotension seen after systemic 
administration of clonidine is bel~eved to be due to 
post-synaptic activation of a 2 -adrencceptors(Kobinger & 
Pichler, 1976i Timmermans et al, 1981) of the 
cardiovascular regulatory centres of the brain. 
Clonidine in its unionized, l ipoph:.. l ic form, crosses 
the blood-brain barrier into the medulla where the 
protonated imidazolidine drug molecules bind to 
a 2 -adrenoceptors (Ruffolo et al, 1982, . Stimulation of 
these receptors results in the inhibition of 
sympathetic outflow together with an increase in 
vaga:L output. The resultant ~asodilation and 
bradycardia lead to a fall in mean arterial pressure. 
Interaction of clonidine with card:..ac prejunctional 
a 2 -adrenoceptors(Huchet et al, 1981) has been found to 
contribute to the bradycardia seen. 
It has also been suggested, that clcnidine may act by 
stimulating presynaptic instead of postsnyaptic 
a 2 -adreno~eptors. These a 2 -adrenoceptors are believed 
to be connected to a facilitatory neurone, the 
stimulation of which results in a reduction of 
peripheral sympathetic tone and a fall in arterial 
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pressure (Van. Zwieten et al, 1973). This mechanism is 
less likely as the hypotensive effects of 
clo~idine(Kobinger & Pichler, 1976) are not abolished 
central noradrenaline stores are depleted by 
' rese~pine or 6-hydroxydopamine. 
Whi:e these are the predominant effects, interactions 
wit~ other blood pressure control mechanisms are known 
to cccur. Baroreceptor and chemoreceptor activity in 
the region of the carotid arteries are amplified. 
Endocrine effects such as a decrease in renin secretion 
and angiotensin-IT levels are seen. Inhibition of 
sec~etion of ACTH and aldosterone leading to a lower 
blocj volume contribute to the hypotension in chronic 
the:::.-a;:>y (vJalland, 1977) . 
The ~edullary site at which clonidine acts and the 
associated nerve pathways involved in the mediation of 
che ~ypotensive and bradycardiac responses have been 
inves~igated intensively in rats and cats. They 
correspond closely with the neural 9athways involved in 
both ~he reflex and tonic control of arterial pressure. 
An ~~ceg~al component of the neuronal circuitry 
invo~ved is the nucleus tractus solitarii(NTS) It has 
been shown that destruction of the NTS reduces but does 
not abolish the hypotensive and bradycardiac effects of 
19 
clc:-:idine, indicating that clonidine has its primary 
sit~ of action elsewhere (Lipski et al, 1976, Zandberg 
et s.l, 1979). 
The NT~ also provides major input to the nucleus 
amo~guus and dorsal motor nucleus of the vagus, which 
is :he site of origin of preganglionic cardiac vagal 
neu~ones. The NTS is known to provide neurones which 
innervate the region of the medulla known as the 
ros:~al ventrolateral medulla(RVLM) which is believed 
to ce responsible for vasomotor tone(Spyer, 1994). The 
RVL~ receives major innervation from the A1 group of 
noradrenergic containing neurones found in the caudal 
vent~olateral medulla which has been shown to further 
:::o:-:: :;:, in a subgroup of adrenergic neurone s, the C1 
gro·..:.9(Spyer, 1994) These neurones are believed to 
relay baroreceptor inputs from the NTS to the RVLM to 
regc::..ate its activity(Granata et al, 1985) The C1 
neur~~s also project into the spinal cord providing 
majc~ innervation for the sympathetic preganglionic 
neurcnes of the intermediolateral cell column(Zagon & 
Smit::O., 1993). The activity of these neurones are 
largely qependent on baroreceptor activity and have 
been observed to fire with a cardiac rythym(Spyer, 
1994) They are believed to be responsible for the 
maintenance of resting levels of arterial 
pressure(Granata et al, 1985) 
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-The RVLM is believed to be the main site of action of 
clonidine in the medulla(Ernsberger et al, 1987; Reis 
et al, 1988) In the framework of the neuronal 
circuits described above, clonidine may be envisaged as 
acting on a 2 -adrenoceptors in the RVLM(Ernsberger et 
al, 198 7) . This causes a reduced sympathetic output 
which is transmitted to the sympathetic preganglionic 
neurones of the intermediolateral cell column. The 
activity of postganglionic sympathetic neurones are 
inhibited by the release of acetylcholine. At the 
level of the blood vessels and the heart, there is a 
modulation in the release of noradrenaline which is 
accompanied by vasodilatation and bradycardia. 
The increase in vagal output may be explained as a 
sti~~~ation of the dorsal vagal nuclei in the pressor 
reg1on of the reticular system of the medulla by 
clo:::.2.::iine. This results in an increase 1n nerve 
acci~ity of the preganglionic cardiac neurones. 
SLbsequently, there is an increased discharge in 
postganglionic cardiac neurones and the release of 
acetylcholine at the synapses in the heart. This 1s 
accompanied by bradycardia. 
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1.4.l(b) Common side-effects of clonidine 
The administration of clonidine in therapy of 
hype~tension is accompanied by a number of side-
effec:ts. Among the most commonly seen during the 
init:..al stages are drowsiness, dry-mouth, dizziness, 
headache and constipation. Less common side-effecti 
are jepression, anxiety, fatigue, nausea, slight 
orttc:static hypotension and impotence. In animals, 
chrc~ic administration of clonidine has been shown to 
proc·..:ce acidosis(Gan & Abdul Satar, 1982). A 
tem~c:rary loss in hypotensive ~fficacy has been 
obser~ed sometimes during clonidine treatment. Fluid 
rete~~ion may be responsible for this phenomenon .. 
A ser:..ous disadvantage of clonidine therapy is the 
appe~rance of withdrawal or rebound hypertension, upon 
abr~~= termination of administration of the drug. The 
cond:=ion is characterised by a rapid increase in blood 
press~re in excess of pre-treatment levels. Some of 
the symptoms seen in this condition are nausea, 
swea=:ng, tachycardia and headache which are symptoms 
' 
of ad~energic overactivity. 
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1.4.1(c). Clinical uses 
Clonidine has its principal use as an antihyper~ensive 
agen:::. Presently, it is not the treatment of ch~ice in 
hypertension and this is mainly due to its tox~city. 
Clonidine may be given either orally or intrave~ously 
in the treatment of hypertension. The oral main~enance 
dose is between 0.3 to 1.2 mg daily but ~~y be 
increased as required. In hypertensive c~~ses, 
clonidine may be given by slow intravenous injecc~on at 
a dose of between 150 to 300 ~g and up to 750 ~g over 
24 hours. Efficacy may be increased by the adiition 
of a diuretic(Kawasaki et al, 1991). 
Clo~~dine has also been used in the treatme~: of 
glauccma. Intraconjunctival instillation of is::::onic 
solu:icns containing 0.125 - 0.5% of clonidine reduces 
int~accular pressure by decreasing aqueous ~umor 
form~:ion and increasing outflow(Huber et al, :.391). 
Clonidine because of its selective stimulat~:n on 
a 2 -aarenoceptors causes a pronounced ocular hypotensive 
response. 
Clonidine has also been used ln the prophylax~s of 
migraine, recurrent vascular headaches and menopausal 
flushing. Other reported uses of clonidine are in the 
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treatment of nervous systems disorders, alcohol and 
opiate withdrawal syndromes(Martindale, 1989). 
1.4.2. Clonidine analogues 
~he chemical synthesis of compounds with a basic 
structure resembling that of clonidine, have provided 
agents that have found usefulness in both the~apeutics 
as well as experimental research. The tritiated form 
of 4-amino-clonidine, is used to label a 2 -adrenoceptors 
(Ernsberger, et al, 1987). Xylazine or 2- (2,6-
dimethylphenylamino)-4H-5,6-dihydro-1,3-thiazine, has 
actions similar to clonidine (Schmitt, 1977). It is 
relatively more selective for a 2 over a 1 -adrenoceptors. 
Xyalzine is used as a veterinary anesthetic. 
1.5. Structure-activity relat~onships of clonidine. 
Clonidine exhibits a potential for tautomerism but has 
been shown to exist predominantly in the imino form(Jen 
et al, 1972). The molecule may be divided into three 
parts consisting. of the aromatic ring, the bridge 
nitrogen and the imidazolidine moiety. Modifications 
have involved each or a combination of anyone of these 
parts. 
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